Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Bibliographic Details
Main Authors: Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T
Format: Online
Language:English
Published: Nature Publishing Group 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950852/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950852/

Similar Items